Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. (TCRT) Revenue
Annual & quarterly revenue history · segment & region breakdown
TCRT · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAlaunos Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 50.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -50.00% |
| 2024-12-31 | $0.00B | +$0.00B | +100.00% |
| 2023-12-31 | $0.00B | -$0.00B | -99.83% |
| 2022-12-31 | $0.00B | +$0.00B | +634.17% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | -$0.00B | -100.00% |
| 2018-12-31 | $0.00B | -$0.01B | -97.71% |
| 2017-12-31 | $0.01B | -$0.00B | -6.88% |
| 2016-12-31 | $0.01B | +$0.00B | +58.38% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Alaunos Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Alaunos Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Alaunos Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
TCRT revenue · 4 questionsTCRT's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 50.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Alaunos Therapeutics, Inc. SEC filings · GAAP · Alaunos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026